JPS59175467A - Ureidobenzamide derivative - Google Patents

Ureidobenzamide derivative

Info

Publication number
JPS59175467A
JPS59175467A JP4884083A JP4884083A JPS59175467A JP S59175467 A JPS59175467 A JP S59175467A JP 4884083 A JP4884083 A JP 4884083A JP 4884083 A JP4884083 A JP 4884083A JP S59175467 A JPS59175467 A JP S59175467A
Authority
JP
Japan
Prior art keywords
formula
give
derivative
ureidobenzamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4884083A
Other languages
Japanese (ja)
Inventor
Narimitsu Honda
本多 成光
Hideaki Nagai
秀明 永井
Akiko Takishima
滝島 章子
Akinori Kawamura
河村 明典
Masuo Koizumi
小泉 益男
Yasushi Murakami
泰 村上
Yoshikazu Hinohara
日野原 好和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP4884083A priority Critical patent/JPS59175467A/en
Publication of JPS59175467A publication Critical patent/JPS59175467A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NEW MATERIAL:An ureidobenzamide derivative shown by the formula I (R1 is H, lower alkyl, or lower alkoxy; R2 is H, halogen, lower alkoxy, or 1-2 lower alkyl; n is 0 or 1). EXAMPLE:3-Ureido-N-2-pyridylbenzamide. USE:A drug having blood sugar lowering action. PREPARATION:For example, a 3-nitrobenzoyl chloride shown by the formula IIis reacted with an amine in the presence of a base, to give a 3-nitrobenzamide derivative shown by the formula III, which is then reduced to give a 3-aminobenzamide derivative shown by the formula IV, which is reacted with an alkali cyanate in an acidic aqueous solution, to give the desired compound shown by the formula I .

Description

【発明の詳細な説明】 本発明は次の一般式 (式中R1は、水素原子、低級アルキル基又は低級アル
コキシ基を示し、R2は水素原子、ハ田ゲン原子、低級
アルコキシ基又は1〜2個のa基を示し、nは0又は1
を示す。)で表わされるウレイドベンズアミドm2i体
に関する。
Detailed Description of the Invention The present invention relates to the following general formula (wherein R1 represents a hydrogen atom, a lower alkyl group, or a lower alkoxy group, and R2 represents a hydrogen atom, a hydrogen atom, a lower alkoxy group, or 1 to 2 a group, n is 0 or 1
shows. ) is related to the ureidobenzamide m2i form.

上式CI)で表わされる本発明の化合物は優れた血糖降
下作用を有し、医薬として有用である。
The compound of the present invention represented by the above formula CI) has an excellent hypoglycemic effect and is useful as a medicine.

本発明の化合物は例えば以下に示すように3−二トロベ
ンゾイルクロライドとアミン類とを塩基の存在下反応さ
せ3−二Fロベンズアミド誘導体とし、次いでこれを常
法により還元して3−アミノベンズアミド誘導体とした
後、酸性水浴液中、シアン酸アルカリと反応させること
により得ることができる。
The compound of the present invention can be produced, for example, by reacting 3-nitrobenzoyl chloride with an amine in the presence of a base to obtain a 3-2F lobenzamide derivative as shown below, and then reducing this by a conventional method to form a 3-aminobenzamide. It can be obtained by making it into a derivative and then reacting it with an alkali cyanate in an acidic water bath.

これを式示すれば以下のとおりである。尚、式中Xは、
ハロゲン原子、Aはアルカリ金属原子を意味し、その他
の記号は前記と同一の意味を有する。
The formula for this is as follows. In addition, in the formula, X is
The halogen atom and A mean an alkali metal atom, and the other symbols have the same meanings as above.

〔■〕〔皿〕 化合物CIIJとアミノピリジン角との反応+1、j1
a常の酸アミド形成反応条件により行われ、例え(ま′
アセトン、テトラヒドロフラン、ジオキ″v−ン等の不
活性溶媒中打丁しくはトリエチルアミン、ピリジン等の
塩基の存在下0〜30℃、1〜5時II号で行われる。
[■] [Dish] Reaction between compound CIIJ and aminopyridine angle +1, j1
a It is carried out under conventional acid amide formation reaction conditions, e.g.
The reaction is carried out in an inert solvent such as acetone, tetrahydrofuran, diquine, etc., or in the presence of a base such as triethylamine, pyridine, etc. at 0 to 30° C. at 1 to 5 o'clock No. II.

化合物〔■〕は常法により、例えばノぐラジウム−炭素
、ラネイニッケル、二酸化白金等の触媒を用いる還元反
応により容易に化合物〔■〕に導くことができる。
Compound [■] can be easily converted into compound [■] by a conventional method, for example, by a reduction reaction using a catalyst such as noradium-carbon, Raney nickel, or platinum dioxide.

化合物〔■〕とシアン酸塩との反応は、通常の尿素形成
反応条件により行われ、例えば化合物■を塩酸、酢酸等
の酸性水浴液に溶解し、次いでシアン酸アルカリ水浴液
を加え、0〜100℃、1〜5時間で行われる。
The reaction between compound [■] and cyanate is carried out under the usual urea formation reaction conditions. For example, compound (■) is dissolved in an acidic water bath solution such as hydrochloric acid or acetic acid, then an alkaline cyanate bath solution is added, and the It is carried out at 100°C for 1 to 5 hours.

実施例1゜ 2−アミノピリジン28.2f、)リエチルアミン45
mg及びアセトン600mgの混合浴液に、水冷(W押
下、3−ニトロベンゾイルクロライド55゜82を徐々
に加える。同温度で30分、次いで室温で1時間攪拌後
、反応浴液を3℃の水Qこ注ぎ、析出する結晶を戸数し
、水洗後メタノールより再結晶して無色針状晶の3−ニ
トロ−N−2−ピリジルベンズアミド58.57を得た
。収率80%。
Example 1゜2-aminopyridine 28.2f,) ethylamine 45
3-nitrobenzoyl chloride was gradually added to a mixed bath solution containing 600 mg of acetone and 600 mg of acetone. The precipitated crystals were collected, washed with water, and then recrystallized from methanol to obtain 58.57 ml of 3-nitro-N-2-pyridylbenzamide in the form of colorless needles. Yield: 80%.

融点156〜157℃。この15.9f、10%パラジ
ウム−炭素1.51及びエタ/−ル300 yttの混
液に水素を通じ、常法により接触還元する。計算量の水
素を吸収後触媒を除去し、反応液を減圧0;1縮し、残
置をエタノールよりp1糸吉晶して包(包金ト状晶(D
 3−アミノ−N−2−ピ1)ジルベンズアミド7.2
L?を得た。収率52%、融点113〜115℃。この
6.42を5%塩酸溶液50y、、J&こ溶解し、室温
(ひ押下、過剰の10%シアン酸力1ノウム水溶液を加
えてアルカリ性とし、同温度で21時間攪指ミを続ける
。析出した結晶を戸数し、水洗後メタノールから再結晶
して無色針状晶の3−ウレイド−N−2−ピリジルベン
ズアミド(イし合物i)5.57を得た。収率72%、
融点223〜224℃。
Melting point: 156-157°C. Hydrogen was passed through this mixture of 15.9 f, 10% palladium-carbon 1.51 and 300 ytt of ethanol, and catalytic reduction was carried out by a conventional method. After absorbing the calculated amount of hydrogen, the catalyst was removed, the reaction solution was concentrated under reduced pressure 0;
3-Amino-N-2-py1)zylbenzamide 7.2
L? I got it. Yield 52%, melting point 113-115°C. Dissolve this 6.42 in 50 ml of 5% hydrochloric acid solution, press down at room temperature, make alkaline by adding an excess of 10% cyanic acid, and continue stirring for 21 hours at the same temperature. Precipitation. The resulting crystals were separated, washed with water, and then recrystallized from methanol to obtain colorless needle-like crystals of 3-ureido-N-2-pyridylbenzamide (Ishi compound I) at a yield of 5.57. Yield: 72%.
Melting point 223-224°C.

元素分析値 分子式013 HI3 N4 o2として
0      )I      N Jフj1 i倫イ直σ功    60.93    4
.72    2]、、87実1jll値(M   6
0.90 4.75 21.88」−記と同様にして表
1の化合物を得)こ。
Elemental analysis value Molecular formula 013 HI3 N4 0 as o2 ) I N J Fu j1 i Lun I Direct σ Gong 60.93 4
.. 72 2],, 87 real 1jll value (M 6
0.90 4.75 21.88'' - The compound shown in Table 1 was obtained in the same manner as described above.

実施例2゜ 1gY−5匹の5週令DDY系マウス(iIf: 、体
重25〜30S’)を16時間絶食後、アロキサン75
prg / kgを静脈内に投与し、48時間後に、本
発明化合物(20011rg/#)の水浴液又はけん濁
液を経口投与し、150分後に心臓から採血し、グルコ
ースオキシダーゼ法により血中糖量を測定した。
Example 2 After fasting for 16 hours, 1gY-5 5-week-old DDY mice (iIf, weight 25-30S') were treated with alloxan 75.
prg/kg was administered intravenously, 48 hours later, a water bath solution or suspension of the compound of the present invention (20011rg/#) was orally administered, and 150 minutes later, blood was collected from the heart and the blood sugar level was determined by the glucose oxidase method. was measured.

測定結果を表2に例示する。The measurement results are illustrated in Table 2.

なお、表中の化合物番号は、実施例1の化合物917号
に対ルーしている。
Note that the compound numbers in the table correspond to compound No. 917 of Example 1.

Claims (1)

【特許請求の範囲】 NHこ0NH2 (式中R1は、水素原子、低級アルキル基又は低級アル
コキシ基を示し、R2は水素原子、ハロゲン原子、低級
アルコキシ基又は1〜2個の低級アルキル基を示し、n
は0又は1を示す。)で表わされるウレイドベンズアミ
ド誘導体。
[Claims] NH0NH2 (in the formula, R1 represents a hydrogen atom, a lower alkyl group, or a lower alkoxy group, and R2 represents a hydrogen atom, a halogen atom, a lower alkoxy group, or 1 to 2 lower alkyl groups) ,n
indicates 0 or 1. ) A ureidobenzamide derivative represented by
JP4884083A 1983-03-25 1983-03-25 Ureidobenzamide derivative Pending JPS59175467A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4884083A JPS59175467A (en) 1983-03-25 1983-03-25 Ureidobenzamide derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4884083A JPS59175467A (en) 1983-03-25 1983-03-25 Ureidobenzamide derivative

Publications (1)

Publication Number Publication Date
JPS59175467A true JPS59175467A (en) 1984-10-04

Family

ID=12814440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4884083A Pending JPS59175467A (en) 1983-03-25 1983-03-25 Ureidobenzamide derivative

Country Status (1)

Country Link
JP (1) JPS59175467A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010380A3 (en) * 1999-08-04 2001-08-16 Icagen Inc Benzanilides as potassium channel openers
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010380A3 (en) * 1999-08-04 2001-08-16 Icagen Inc Benzanilides as potassium channel openers
US6372767B1 (en) 1999-08-04 2002-04-16 Icagen, Inc. Benzanilides as potassium channel openers
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6605725B2 (en) 1999-08-04 2003-08-12 Icagen, Inc. Benzanilides as potassium channel openers
US6989398B2 (en) 1999-08-04 2006-01-24 Icagen, Inc. Benzanilides as potassium channel openers

Similar Documents

Publication Publication Date Title
EP0014951B1 (en) Heterocyclic oxypropanolamine derivatives, process for their preparation and medicines containing these compounds
JPS5943459B2 (en) N-alkylpiperidine derivative
EP0165422B1 (en) Substituted bis-(4-aminophenyl)-sulphones, their preparation and their use as medicines
CA1090347A (en) 1-isopropylamino-3-(3-pyridyloxy)-2-propanol compounds
JPH03141258A (en) Novel piperazine derivative
EP0014928A1 (en) Piperidinopropyl derivatives, process for their preparation and medicaments containing these compounds
JPS59175467A (en) Ureidobenzamide derivative
JPS59181257A (en) Ureidobenzamide derivative
US3845123A (en) Phenoxypropanolamine therapeutic agents
JPS5867657A (en) Benzamide derivative
Baltzly et al. Amines Related to 2, 5-Dimethoxyphenethylamine. 1 I
RU2712036C2 (en) Indolinone derivatives having melatonin receptor ligand properties and use thereof
US4448989A (en) N-Nitroxyalkylene benzamide derivatives
JPS6183163A (en) Antitumoral
JPH034074B2 (en)
JPS59184162A (en) Quinoline derivative, manufacture and 5-ht antagonistic pharmaceutical composition
US4521606A (en) 5-Indolyl substituted aminoethanols
JPH05201978A (en) N-(4,7-dimethoxy-2-indanyl)-1-(phenylcarbonyl)-n-propyl-4- piperidinemethaneamine derivative,its production,and its use as medicine
JPS5984868A (en) Ureidobenzamide
EP0029992A1 (en) Aminopropanol derivatives, process for their preparation and pharmaceutical compositions containing these compounds
El Khadem et al. Synthesis of 8-(3'-deoxy-. alpha.-D-threo-pentofuranosyl) adenine and 9-(3'-deoxy-. alpha.-D-threo-pentofuranosyl) adenine
JPS6011707B2 (en) 1-Carboxyalkylcarbamoyl-5-fluorouracil derivative and method for producing the same
JPS6010034B2 (en) Method for producing 3,4-dihydrocarbostyryl derivative
JPS61233678A (en) Benzylpiperazine derivative
CN113754585A (en) Novel tetrahydroisoquinoline compound and preparation method and application thereof